Revenue, 2025

USD 20.34 Billion

Forecast, 2035

USD 27.68 Billion

CAGR, 2026-2035

3.13%

Report Coverage

Global

Human Insulin Market Trends for 2026

The global human insulin market size was estimated at USD 20.34 billion in 2025 and is predicted to increase from USD 20.97 billion in 2026 to approximately USD 27.68 billion by 2035, expanding at a CAGR of 3.13% from 2026 to 2035.

Due to the growing diabetes burden globally, the demand for human insulin products is increasing. Therefore, the companies are investing in and launching various products, where AI is also being used to develop new systems. Additionally, the robust healthcare, growing investments, and advancing biosimilars are also increasing their use across various regions, promoting the market growth.

Key Takeaways

• Human insulin sector pushed the market to USD 20.97 billion by 2026.
• Long-term projections show USD 27.68 billion valuation by 2035.
• Growth is expected at a steady CAGR of 3.13% in between 2026 to 2035.
• North America held the major revenue share of 40% in the global human insulin market in 2025.
• Asia Pacific is expected to be the fastest-growing region with a CAGR of 9.0% between 2026-2035.
• By product type, the rapid-acting insulin segment held a 50% share in the market in 2025.
• By product type, the long-acting insulin segment is expected to grow with the fastest CAGR of 8.0% during the forecast period.
• By formulation type, the injectable segment held a 65% share in the human insulin market in 2025.
• By formulation type, the inhalable segment is expected to be the fastest-growing with a CAGR of 8.5% during the forecast period.
• By end user type, the hospitals segment held a 45% share in the market in 2025.
• By end user type, the homecare/patients segment is expected to grow with the fastest CAGR of 8.0% during the forecast period.
• By application type, the type 1 diabetes segment held a 50% share in the market in 2025.
• By application type, the type 2 diabetes segment is expected to grow with the fastest CAGR of 8.0% during the forecast period.
• By distribution channel type, the hospital pharmacies segment held a 45% share in the human insulin market in 2025.
• By distribution channel type, the online pharmacies segment is expected to be the fastest-growing with a CAGR of 9.0% during the forecast period.

What is Human Insulin?

The human insulin market is driven by growing global incidences of diabetes, increasing geriatric population, and advancements in insulin delivery technologies. Human insulin is a biologically identical form of insulin produced through recombinant DNA technology or extracted from human sources, used to manage diabetes mellitus. It helps regulate blood glucose levels in patients with type 1 and type 2 diabetes, providing effective glycemic control and reducing complications associated with hyperglycemia.

AI Technological Shifts in the Human Insulin Market

The use of AI in the market is increasing, where it is being used in the identification of blood glucose patterns for the development of personalized insulin dosing. It also helps in managing the blood glucose fluctuations, which is driving the development of the insulin delivery devices. It is also being used for remote patient monitoring and adjusting the insulin regimen depending on the patient's profile.

Trends and Future Outlook of Human Insulin Market

Embracing Biosimilars

There is a rise in the use of insulin biosimilars, where their affordability and accessibility are increasing their use, which in turn is also driving their production and innovations.

Shift Towards Advanced Technologies

The industries are developing various novel technologies such as smart delivery devices, remote monitoring systems, insulin pumps, etc, which are increasing their use for accurate dosing and enhancing patient convenience.

Rising Long-Acting Insulin Adoption

To avoid the frequent dosing of insulin, the patients are increasingly adopting the long-acting insulin formulation, which are also being used for a chronic period of time, where their once-a-day approach is also driving their demand.

Major Investments or Government in the Human Insulin Market

• In August 2025, a $23.6M Series A financing round was announced to be closed by Luna Health Inc., where the funding will be utilized to accelerate the development of the world's smallest insulin patch pump for diabetes patients relying on insulin pens.
• In July 2025, a total of ₹6.5 crore in a Pre-Series A funding round was secured by Lamark Biotech, which will be used to support the entry of InsulinStrong, which is a heat-stable insulin, into India’s insulin market.

Quick Facts Table

Segmental Insights

By Product Insights

Why Did the Rapid-Acting Insulin Segment Dominate in the Human Insulin Market in 2025?

The rapid-acting insulin segment led the market with a 50% share in 2025, due to its fast control over the blood glucose level. This, in turn, increased their use in gestational diabetes, which offered low fetal risk. Additionally, their fixed dose increased patient convenience and promoted their adherence to the treatment.

Long-Acting Insulin

The long-acting insulin segment is expected to show the fastest growth rate with a CAGR of 8.0% during the predicted time, as it reduces the dosing frequency, enhancing patient convenience. They also reduce the risk of hypoglycemia. Additionally, their growing innovation and combination with other insulin therapies are also increasing their use.

By Formulation Insights

How the Injectable Segment Dominated the Human Insulin Market in 2025?

The injectable segment held the largest share of 65% in the market in 2025, as it offers accurate dosing. At the same time, it also provided rapid absorption and bioavailability, which increased its use in emergency situations as well. Furthermore, their widespread availability also increased their use.

Inhalable

The inhalable segment is expected to grow with the fastest CAGR of 8.5% during the predicted time, driven by its non-invasive approach. Their portability and rapid onset of action are increasing the patient convenience and acceptance rates, respectively. Moreover, they are being used for self-management.

By End User Insights

Why Hospitals Segment Dominated the Human Insulin Market in 2025?

The hospitals segment led the market with a 45% share in 2025, due to high patient volume. Hospitals are also considered the primary site for insulin therapies, where the presence of specialized professionals offers safe and accurate insulin administration. This enhanced the patient trust, where the use of advanced solutions also attracted them.

Homecare/Patients

The homecare/patients segment is expected to show the highest growth with a CAGR of 8.0% during the predicted time, due to a growing shift towards self-administration. Additionally, the growing remote monitoring and digital health platforms are also increasing their use to enhance patient convenience and comfort.

By Application Insights

Which Application Type Segment Held the Dominating Share of the Human Insulin Market in 2025?

The type 1 diabetes segment held the dominating share of 50% in the market in 2025, as they rely on insulin therapy. This, in turn, increased the use of rapid-acting insulin products. Moreover, their early onset also increased the use of long-acting insulin solutions for a longer duration of time.

Type 2 Diabetes

The type 2 diabetes segment is expected to be the fastest-growing, with a CAGR of 8.0% during the upcoming years, due to its increasing incidence rates. The growing lifestyle and dietary changes, along with increasing awareness, are increasing their early detection. This is driving the demand for human insulin solutions

By Distribution Channel Insights

What Made Hospital Pharmacies the Dominant Segment in the Human Insulin Market in 2025?

The hospital pharmacies segment led the market with a 45% share in 2025, as they provided direct access to the patients. They also offered proper dosing and monitoring of the patients. Additionally, they also provided complex insulin therapies, where their counseling enhanced patient adherence.

Online Pharmacies

The online pharmacies segment is expected to show the highest growth with a CAGR of 9.0% during the upcoming years, as they provide direct-to-patient deliveries. They also offer a wide range of insulin products and devices, where their home delivery increases access to these products and enhances patient convenience.

Regional Distribution

• North America held the dominance in the market by 40% share in 2025.  
• The U.S. led the market by capturing the largest revenue share of the market in 2025.
• Asia Pacific is expected to be the fastest-growing region in the studied years.
• India is anticipated to grow at a rapid CAGR during the forecast period.
• Europe is expected to grow at a notable CAGR in the human insulin market during the forecast period.
• The UK is anticipated to grow at a rapid CAGR during the forecast period.

Advanced Healthcare Drives North America

North America dominated the human insulin market with 40% in 2025, due to the presence of a well-developed healthcare infrastructure. The growth in the diabetes incidence also increased the demand and use of human insulin. Additionally, the early adoption of various insulin therapies and devices also promoted the development of new insulin formulations by the companies, which contributed to the market growth.

U.S. Market Trends

The U.S. has a dominant role in the growth of the human insulin market, serving as the largest revenue-generating region as well as a major driver of pricing, product innovation, and policy reform. US also generates disproportionately high revenue per unit compared to Europe or Asia, further fueling the market’s growth. The region also favors insulin analogs over traditional human insulin, further fueling the growth of the market. Major domestic and international players of the market account US as a primary Launchpad for normal delivery systems, smart pens, and combination treatments, helpful for market’s growth.

The growth in healthcare investments is promoting the adoption of insulin therapies and their delivery devices in the U.S. At the same time, the growing incidence of diabetes is also increasing the demand for human insulin. Additionally, the increasing cases of obesity and geriatric populations are also contributing to their increasing use.

Canada Market Trends

Canada also has a primary contribution to the growth of the human insulin market. Factors supporting the growth of the market are historic scientific foundation, ongoing domestic market expansion, and regulatory framework. The region is also known to represent the largest and fastest-growing segment of the Canadian insulin market, shifting utilization away from older human and animal formulations. The market’s growth is also driven by the growth of the aging population and rising diabetes prevalence in the region, leading to the broader Canadian diabetes devices and therapeutics sector continuing to expand rapidly.

Growing Diabetes Incidences Boost Asia Pacific

Asia Pacific is expected to host the fastest-growing human insulin market with a CAGR of 9.0% during the forecast period, due to the growing incidence of diabetes. The expanding healthcare sector is also increasing the adoption of various novel insulin therapies, which is driving their products and innovations. The growing awareness and government initiatives are also increasing their use, enhancing the market growth.

China Market Trends

China is a major driver of the human insulin market. The growth of the market in the country is fueled by the world’s largest patient population, massive domestic manufacturing, and aggressive government price-control policies. The massive, high-volume recurring demand pool that anchors global production and consumption trends also fuels the market’s growth. The large-scale domestic production by local industry leaders for traditional human insulins and modern biosimilars is also one of the major market growth factors.

India Market Trends

Cost-effective biosimilar manufacturing, global supply to emerging economies, and high domestic demand driven by a massive patient base are some of the major factors supporting the growth of the human insulin market in India. The Indian biotech and pharmaceutical companies have helped the country to break the long-standing oligopoly of Western giants by producing affordable biosimilars and interchangeable insulins, further propelling market’s growth.

The presence of a large population, lifestyle changes, and rapid urbanization is increasing the diabetes burden. At the same time, the growing awareness is also increasing the demand for human insulin products. The industries are also developing affordable insulin products and their analogs, which are increasing their adoption rates.

Europe Driven by Growing Geriatric Population 

Europe is expected to grow significantly in the human insulin market with a CAGR of 7.5% during the forecast period, due to the increasing geriatric population. This, in turn, is increasing the incidence of type 2 diabetes, which is driving the adoption of biosimilar insulin products. Moreover, the industries are developing various formulations and delivery devices, which are promoting the market growth.

UK Market Trends

Due to the presence of robust reimbursement policies, the use of human insulin in the UK is increasing. The growing prevalence of diabetes cases due to increasing sedentary lifestyles and the geriatric population is also driving their demand. Moreover, growing government initiatives are encouraging their innovations, where online platforms are also increasing their accessibility.

Who are the Top Vendors in the Human Insulin Market and What are Their Offerings?

SWOT Analysis

Strength

• The growing incidence of type 1 diabetes is increasing the use of human insulin, as it is mandatory in these patients, due to a lack of insulin alternatives.
• The human insulin offers enhanced safety and effectiveness, which is increasing its adoption rates across the healthcare sector.
• To deal with the growing diabetes burden, the government is also encouraging the use of human insulin, where they are also offering reimbursement and insurance policies.
• The industries are also developing advanced long-acting and next-generation insulin analogs to deliver effective treatment options for diabetic patients.

Weakness

• High cost acts as the major weakness in the human insulin market, as it reduces their use and affects the adherence of the patient to the treatment.
• Moreover, the risk of hypoglycemia is also associated with the use of human insulin, which limits its adoption rates.

Opportunity

• Growing health awareness is driving the early diagnosis of diabetes, which is increasing the use of insulin therapies.
• The demand for biosimilars is increasing, as their growing innovations, affordability, and availability are increasing their use.
• The companies are developing novel insulin delivery systems with an aim to enhance patient convenience and adherence to the treatment, where they are also developing online platforms for personalized diabetes management and remote monitoring.

Threats

• Human insulin manufacturing requires advanced biotechnology and stringent manufacturing standards, which makes its production process more complex.
• Human insulin must be stored under controlled temperature, where it requires cold chain storage, which limits its adoption across limited storage facilities, limiting their accessibility.

Human Insulin Market Value Chain Analysis

R&D

• The R&D of human insulin involves the development of once-weekly basal insulin, non-invasive methods, and smart microneedle patches.
• Key players: Sanofi, Novo Nordisk, Eli Lilly and Company.

Clinical Trials and Regulatory Approvals

• Clinical trials and regulatory approval of the human insulin focus on the demonstration of their bioequivalence, safety, and efficacy.
• Key players: Novo Nordisk, Biocon Limited.

Patient Support and Services

• Patient assistance programs, copay saving cards, educational materials, and injection training are offered in the patient support and services of human insulin.
• Key players: Sanofi, Novo Nordisk, Eli Lilly and Company.

What are the Recent Developments in the Human Insulin Market?

• In July 2025, Kirsty (Insulin Aspart-xjhz) 100 units/ml, a rapid-acting human insulin analog and biosimilar to Novolog, was announced to have received U.S. FDA approval for glycemic control in pediatric and adult diabetes mellitus patients.
• In February 2025, Merilog, developed by Meitheal Pharmaceuticals and Tonghua Dongbao Pharmaceutical to enhance insulin accessibility and affordability for Americans with diabetes, was announced to have received U.S. FDA approval.

Segments Covered in the Report

By Product

• Rapid-Acting Insulin
• Insulin Aspart
• Insulin Lispro
• Short-Acting Insulin
• Regular Insulin
• Intermediate-Acting Insulin
• NPH Insulin
• Long-Acting Insulin
• Insulin Glargine
• Insulin Detemir

By Formulation

• Injectable
• Inhalable

By End User

• Hospitals
• Clinics
• Homecare/Patients
• Research Institutes

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
• Eastern Europe
  • Austria
  • Russia & Belarus
  • Türkiye
  • Albania
  • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  • GCC Countries
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA